medgenМедицинская генетикаMedical Genetics2073-7998Publishing House «Genius Media» LLCmedgen-249Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHПромоторный полиморфизм rs890293 гена эпоксигеназы CYP2J2 ассоциирован с повышенным риском развития гипертонической болезни у женщинThe Promoter Polymorphism rs890293 of the CYP2J2 Gene Is Associated with An Increased Risk of Essential Hypertension in WomenБыкановаМ. А.BykanovaM. A.marina.bickanova@yandex.ruСолодиловаМ. А.SolodilovaM. A.noemail@neicon.ruБочароваА. В.BocharovaA. V.noemail@neicon.ruВагайцеваК. В.VagaytsevaK. V.noemail@neicon.ruСтепановВ. А.StepanovV. A.noemail@neicon.ruПолониковА. В.PolonikovA. V.noemail@neicon.ruКурский государственный медицинский университетРоссияKursk State Medical UniversityRussian FederationТомский национальный исследовательский медицинский центр Российской академии наукРоссияTomsk National Research Medical Center of The Russian Academy of SciencesRussian Federation2017190920171633740Copyright © Быканова М.А., Солодилова М.А., Бочарова А.В., Вагайцева К.В., Степанов В.А., Полоников А.В., 20172017Быканова М.А., Солодилова М.А., Бочарова А.В., Вагайцева К.В., Степанов В.А., Полоников А.В.Bykanova M.A., Solodilova M.A., Bocharova A.V., Vagaytseva K.V., Stepanov V.A., Polonikov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medgen-journal.ru/jour/article/view/249

Полиморфный вариант -76G>T (rs890293) гена CYP2J2 показал статистически значимые различия в распределении частот генотипов при сравнении групп больных ГБ (n = 960) и здоровых женщин (n = 552). Гетерозиготный генотип -76G/T ассоциировался с повышенным риском развития ГБ у женщин.

Polymorphism -76G>T (rs890293) of the CYP2J2 gene showed significant differences in the distribution of genotypes between hypertensive and healthy women. In particular, the heterozygous genotype -76G/T was associated with increased risk of developing essential hypertension in women.

гипертоническая болезньДНК-полиморфизмарахидоновая кислотаCYP2J2hypertensive diseaseDNA polymorphismarachidonic acidCYP2J2ReferencesГогин Е.Е. Гипертоническая болезнь - основная причина, определяющая сердечно-сосудистую заболеваемость и смертность в стране. Терапевтический архив. 2003; Т. 75, №9: С. 31-36.Гогин Е.Е. Гипертоническая болезнь - основная причина, определяющая сердечно-сосудистую заболеваемость и смертность в стране. Терапевтический архив. 2003; Т. 75, №9: С. 31-36.Beshay N.M. Zordoky, Ayman O.S. El-Kadi Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacology and Therapeutics. 2010;125:446-463.Beshay N.M. Zordoky, Ayman O.S. El-Kadi Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacology and Therapeutics. 2010;125:446-463.Fichtlscherer, S., Dimmeler, S., Breuer, S. et al. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxidemediated vasodilatation in patients with coronary artery disease. Circulation. 2004; 109(2): 178-183.Fichtlscherer, S., Dimmeler, S., Breuer, S. et al. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxidemediated vasodilatation in patients with coronary artery disease. Circulation. 2004; 109(2): 178-183.Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: Their roles and interactions with lipid metabolism. Progress in lipid research. 2005; 44: 1-51.Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: Their roles and interactions with lipid metabolism. Progress in lipid research. 2005; 44: 1-51.Yang W, Gauthier KM, Reddy LM. et al. Stable 5,6-epoxyeicosatrienoic acid analog relaxes coronary arteries through potassium channel activation. Hypertension. 2005; 45: 681-686.Yang W, Gauthier KM, Reddy LM. et al. Stable 5,6-epoxyeicosatrienoic acid analog relaxes coronary arteries through potassium channel activation. Hypertension. 2005; 45: 681-686.Westphal C, Konkel A, Schunck WH. CYP-eicosanoids-a new link between omega-3 fatty acids and cardiac disease. Prostaglandins & OtherLipidMediators. 2011; 96: 1-4.Westphal C, Konkel A, Schunck WH. CYP-eicosanoids-a new link between omega-3 fatty acids and cardiac disease. Prostaglandins & OtherLipidMediators. 2011; 96: 1-4.Dutheil F, Dauchy S, Diry M. et al. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: Regional and cellular mapping as a basis for putative roles in cerebral function. Drug metabolism and disposition: the biological fate of chemicals. 2009; 37: 1528-1538.Dutheil F, Dauchy S, Diry M. et al. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: Regional and cellular mapping as a basis for putative roles in cerebral function. Drug metabolism and disposition: the biological fate of chemicals. 2009; 37: 1528-1538.Spiecker M., Darius H., Hankeln T. et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation. 2004; 110: 2132-2136.Spiecker M., Darius H., Hankeln T. et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation. 2004; 110: 2132-2136.Florian H., Babbette L.M., Carl A.H. et al. Cytochrome p450 subfamily 2j polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia. Circulation. 2012; 126: 2990-2999.Florian H., Babbette L.M., Carl A.H. et al. Cytochrome p450 subfamily 2j polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia. Circulation. 2012; 126: 2990-2999.Fava C, Montagnana M, Almgren P. et al. The common functional polymorphism -50G>T of the CYP2J2 gene is not associated with ischemic coronary and cerebrovascular events in an urban-based sample of Swedes. Journal of Hypertension. 2010 Feb; 28: 294-299.Fava C, Montagnana M, Almgren P. et al. The common functional polymorphism -50G>T of the CYP2J2 gene is not associated with ischemic coronary and cerebrovascular events in an urban-based sample of Swedes. Journal of Hypertension. 2010 Feb; 28: 294-299.Polonikov A.V., Ivanov V.P., Solodilova M.A. et al. A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population. Disease Markers. 2008; 24: 119-126.Polonikov A.V., Ivanov V.P., Solodilova M.A. et al. A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population. Disease Markers. 2008; 24: 119-126.Маниатис Т., Фрич Э., Сэмбрук Д. Методы генной инженерии. Молекулярное клонирование. М.: Мир, 1984; 480 С.Маниатис Т., Фрич Э., Сэмбрук Д. Методы генной инженерии. Молекулярное клонирование. М.: Мир, 1984; 480 С.http://browser.1000genomes.org/Homo_sapiens/Variation/Populationhttp://browser.1000genomes.org/Homo_sapiens/Variation/PopulationPinsonneault J., Sadee W. Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome. AAPS Pharm Sci. 2003; 5: E29.Pinsonneault J., Sadee W. Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome. AAPS Pharm Sci. 2003; 5: E29.King L.M., Gainer J.V., David G.L. et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics. 2005; 15: 7-13.King L.M., Gainer J.V., David G.L. et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics. 2005; 15: 7-13.Zhu Q, Fu Z, Ma Y. et al. A novel polymorphism of the CYP2J2 gene is associated with coronary artery disease in Uygur population in China. Clin Biochem. 2013;46(12):1047-1054.Zhu Q, Fu Z, Ma Y. et al. A novel polymorphism of the CYP2J2 gene is associated with coronary artery disease in Uygur population in China. Clin Biochem. 2013;46(12):1047-1054.Fleming I. The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease. Pharmacological Reviews. 2014; 66(4): 1106-1140.Fleming I. The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease. Pharmacological Reviews. 2014; 66(4): 1106-1140.

The authors declare that there are no conflicts of interest present.